Affimed (AFMD) Shows Strength: Stock Moves 6.7% Higher

Affimed N.V. AFMD was a big mover last session with its shares rising roughly 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained over 23% since Nov 13.

This clinical-stage biopharmaceutical company has seen one positive estimate revision in the last 30 days. However, the Zacks Consensus Estimate has remained unchanged over the same period. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

Affimed currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Med-Drugs space may consider Corcept Therapeutics Inc. CORT, which sports a Zacks Rank #1 (Strong Buy).

Is AFMD going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.